Clinical Trial Update: A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A study of MRG003 in EGFR-positive advanced or metastatic solid tumors is ongoing in Phase 1/2; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-positive Solid Tumors
• Solid Tumors

Drugs mentioned

• MRG003

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: UNKNOWN